A medicinal composition includes an active herbal component that is prepared by cooking a combination of Sheng Di Huang, Da Huang and Jin Yin Hua and has an average particulate size between 100-300 nm. Example formulations include topical gels, tablets and capsules.

A medicinal composition includes an active herbal component that is prepared by cooking a combination of Sheng Di Huang, Da Huang and Jin Yin Hua and has an average particulate size between 100-300 nm. Example formulations include topical gels, tablets and capsules.

A medicinal composition includes an active herbal component that is prepared by cooking a combination of Sheng Di Huang, Da Huang and Jin Yin Hua and has an average particulate size between 100-300 nm. Example formulations include topical gels, tablets and capsules.

There is disclosed a clear skin supplement/medicinal component for acne comprising: an orally administered dosage comprising of between about 3000-9000 mg of the Chinese medicinal composition comprising by ratio: around 3.8-7.6% of each of Prunus persica, Carthamus tinctorius, Angelica dahurica, Gleditsia sinensis, Viola yedoensis, Paeonia suffruticosa and gardenia jasminoides; around 5.7-7.6% of each of Oldenlandia diffusa and Scutellaria baicalensis; around 3.8-5.7% of Salvia miltiorrhiza; around 2.5-5.7% of Phellodendron amurense; around 2.5-7.6% of Gentiana scabra; and around 0-7.6% of each of Taraxacum mongolicum and any one of Lonicera japonica/Rhizoma Coptidas/Sophora flavescens.

There is disclosed a clear skin supplement/medicinal component for acne comprising: an orally administered dosage comprising of between about 3000-9000 mg of the Chinese medicinal composition comprising by ratio: around 3.8-7.6% of each of Prunus persica, Carthamus tinctorius, Angelica dahurica, Gleditsia sinensis, Viola yedoensis, Paeonia suffruticosa and gardenia jasminoides; around 5.7-7.6% of each of Oldenlandia diffusa and Scutellaria baicalensis; around 3.8-5.7% of Salvia miltiorrhiza; around 2.5-5.7% of Phellodendron amurense; around 2.5-7.6% of Gentiana scabra; and around 0-7.6% of each of Taraxacum mongolicum and any one of Lonicera japonica/Rhizoma Coptidas/Sophora flavescens.

There is disclosed a clear skin supplement/medicinal component for acne comprising: an orally administered dosage comprising of between about 3000-9000 mg of the Chinese medicinal composition comprising by ratio: around 3.8-7.6% of each of Prunus persica, Carthamus tinctorius, Angelica dahurica, Gleditsia sinensis, Viola yedoensis, Paeonia suffruticosa and gardenia jasminoides; around 5.7-7.6% of each of Oldenlandia diffusa and Scutellaria baicalensis; around 3.8-5.7% of Salvia miltiorrhiza; around 2.5-5.7% of Phellodendron amurense; around 2.5-7.6% of Gentiana scabra; and around 0-7.6% of each of Taraxacum mongolicum and any one of Lonicera japonica/Rhizoma Coptidas/Sophora flavescens.

The present invention pertains to a Lonicera Japonica flower water extract composition for preventing or treating Helicobacter pylori infection, the composition containing secoxyloganin as an active ingredient. The extract contains a specific amount of secoxyloganin, and thus exhibited excellent antibacterial effects when used on Helicobacter pylori bacteria, and exhibited excellent effects in terms of reducing Helicobacter pylori IgG antibody expression in the blood, alleviating histopathological lesions, and reducing cytokine expression when used on Helicobacter pylori-infected mice. Thus, the Lonicera Japonica flower water extract of the present invention can be usefully used as a composition for preventing or treating Helicobacter pylori infection.

The present invention pertains to a Lonicera Japonica flower water extract composition for preventing or treating Helicobacter pylori infection, the composition containing secoxyloganin as an active ingredient. The extract contains a specific amount of secoxyloganin, and thus exhibited excellent antibacterial effects when used on Helicobacter pylori bacteria, and exhibited excellent effects in terms of reducing Helicobacter pylori IgG antibody expression in the blood, alleviating histopathological lesions, and reducing cytokine expression when used on Helicobacter pylori-infected mice. Thus, the Lonicera Japonica flower water extract of the present invention can be usefully used as a composition for preventing or treating Helicobacter pylori infection.

The invention discloses an application of phlegmyheatclear in preparation of a drug for treatment of acute exacerbation of chronic obstructive pulmonary disease. The present invention studies the effect of phlegmyheatclear on model of rats with acute exacerbation of chronic obstructive pulmonary disease. Results show that high dose, middle dose, or low dose of phlegmyheatclear can, during the acute exacerbation of chronic obstructive pulmonary disease, improve the lung function of the rats and the pathological damage of lung tissues of the rats in different degrees, and it is dose dependent. High dose, middle dose, or low dose of phlegmyheatclear can improve inflammatory reaction in different degrees. For the drug effects, the high dose and the middle dose of phlegmyheatclear are better than the low dose of phlegmyheatclear. Therefore, phlegmyheatclear can be used to prepare a drug for treatment of acute exacerbation of chronic obstructive pulmonary disease.

The invention discloses an application of phlegmyheatclear in preparation of a drug for treatment of acute exacerbation of chronic obstructive pulmonary disease. The present invention studies the effect of phlegmyheatclear on model of rats with acute exacerbation of chronic obstructive pulmonary disease. Results show that high dose, middle dose, or low dose of phlegmyheatclear can, during the acute exacerbation of chronic obstructive pulmonary disease, improve the lung function of the rats and the pathological damage of lung tissues of the rats in different degrees, and it is dose dependent. High dose, middle dose, or low dose of phlegmyheatclear can improve inflammatory reaction in different degrees. For the drug effects, the high dose and the middle dose of phlegmyheatclear are better than the low dose of phlegmyheatclear. Therefore, phlegmyheatclear can be used to prepare a drug for treatment of acute exacerbation of chronic obstructive pulmonary disease.